ConductScience.org, home

Paper42474263

A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.

Bai YR and 6 others. J Enzyme Inhib Med Chem, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect. Papers, record 42474263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42474263

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.
PubMed
Journal
J Enzyme Inhib Med Chem
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bai YRYi-Ru
2Li RRuifang
3Zhang XHXin-Hui
4Seng DJDong-Jie
5Xu YYing
6Zhang SYSai-Yanghttps://orcid.org/0000-0003-4395-8879
7Yuan SShuo

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Small Molecule LibrariesMajor topic
Drug ApprovalMajor topic
United States
Humans
United States Food and Drug Administration
Structure-Activity Relationship
Molecular Structure
Drug Design

Source PubMed

Download CSV of topics

References95

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138101437
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Lancet Respir Med2024https://conductscience.org/library/papers/38101437PubMed
238400780Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Neuro Oncol2024https://conductscience.org/library/papers/38400780PubMed
339700833Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.Eur J Cancer2025https://conductscience.org/library/papers/39700833PubMed
440069319Upcoming FDA approval decisions in Q2 2025.Nat Rev Drug Discov2025https://conductscience.org/library/papers/40069319PubMed
535961460Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).Bioorg Med Chem Lett2022https://conductscience.org/library/papers/35961460PubMed
636768346Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development.Int J Mol Sci2023https://conductscience.org/library/papers/36768346PubMed
786763392,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.J Med Chem1996https://conductscience.org/library/papers/8676339PubMed
820686482Type IIA topoisomerase inhibition by a new class of antibacterial agents.Nature2010https://conductscience.org/library/papers/20686482PubMed
938822758Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.J Clin Oncol2024https://conductscience.org/library/papers/38822758PubMed
1039869433New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer.Annu Rev Med2025https://conductscience.org/library/papers/39869433PubMed
1140030100HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.J Clin Oncol2025https://conductscience.org/library/papers/40030100PubMed
1239824516Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.J Med Chem2025https://conductscience.org/library/papers/39824516PubMed
1339248702Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.Cancer Discov2025https://conductscience.org/library/papers/39248702PubMed
1440266575Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.JAMA Dermatol2025https://conductscience.org/library/papers/40266575PubMed
1539196032Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Nat Cardiovasc Res2024https://conductscience.org/library/papers/39196032PubMed
1634002056Kinase drug discovery 20 years after imatinib: progress and future directions.Nat Rev Drug Discov2021https://conductscience.org/library/papers/34002056PubMed
1739940712Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.Int J Mol Sci2025https://conductscience.org/library/papers/39940712PubMed
1834606259Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.J Med Chem2021https://conductscience.org/library/papers/34606259PubMed
1932348841Tetrahydrobiopterin in energy metabolism and metabolic diseases.Pharmacol Res2020https://conductscience.org/library/papers/32348841PubMed
2037211904New drug approvals for 2022: Synthesis and clinical applications.Med Res Rev2023https://conductscience.org/library/papers/37211904PubMed

See all 95 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42883213Small-Molecule Drugs Approved by the FDA in 2025.Molecules2026https://conductscience.org/library/papers/42883213

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42474263

GET https://conductscience.org/api/papers/v1/42474263/references?page=2